53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes ... portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as ...

ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...

The findings demonstrate that AD disease activity remained mild in patients who had achieved ... Biologics License Application (BLA) for HLX14, biosimilar candidate of PROLIA/XGEVA (denosumab).

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Improving the competitive landscape for biosimilars should be an essential part of this strategy. The expected result from the increased competition will be reduced costs for patients and lower ...

Alvotech’s CEO highlighted the move as a significant step towards strengthening the company’s position in the biosimilars market and enhancing patient access to biologics globally. Acquisition ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Given the high cost of branded drugs, a biosimilar alternative could provide substantial financial relief to patients and healthcare systems. Additionally, with osteoporosis affecting millions ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...